Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHASTA-10 open-label extension of plozasiran in adults with severe hypertriglyceridemia
CTR20252375Phase 3Active
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Dec 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of plozasiran in hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals. Started Dec 2025; status: active.
02
Drugs
plozasiran
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on CTR20252375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252375.